Chapter 3: The HIV-Tainted Blood Scandal — Government and Corporations Prioritizing Profit Over Lives
1. Introduction
In the 1980s, a widely used treatment in Japanese medical settings to stop bleeding in hemophilia patients was unheated blood products.
However, these products were contaminated with the human immunodeficiency virus (HIV), bringing a new disease to patients.
A "medicine meant to save lives" causing a fatal infection—this is one of the most serious tragedies in the history of drug-induced suffering.
2. Timeline and Delayed Response
1982 (USA) The possibility of HIV infection through blood products is reported.
1983 (USA/France) HIV is detected in hemophilia patients, and it is confirmed that it can be rendered harmless through heat treatment.
1985 (USA) Heat-treated products are introduced in the US, and the use of unheated products is discontinued.
1985 (Japan) Japan also approves heat-treated products, but prioritizes the disposal of corporate inventory, meaning the recall and cessation of use of unheated products are not thoroughly enforced, and distribution continues.
1987 and later Numerous HIV infections are confirmed, primarily among hemophilia patients.
The Ministry of Health, Labour and Welfare also records: "Despite the introduction of heat-treated products in the US, unheated products were used for a long period in Japan, and many patients were infected with HIV" (Ministry of Health, Labour and Welfare, 'History of Drug-Induced Suffering').
A response several years behind overseas caused fatal damage.
3. Reality of the Damage
Infected individuals: Approximately 2,000 (primarily hemophilia patients)
Many were young. Treatment for their condition became associated with a "deadly disease." Families were forced to live lives "hiding the infection" and suffered from discrimination and prejudice.
Voices of the victims: "I thought I would get better if I received treatment through blood transfusions. Who could have believed that it would become a death sentence?" (From a collection of testimonies by HIV-tainted blood scandal victims) "It was my hands that injected the medicine into my son. I felt crushed by the guilt of being a mother." (From a victim's family member's journal)
4. Why Did Use Continue?
Corporate interests: Prioritized the disposal of unheated product inventory and delayed the switch.
Administrative stance: Did not move to an immediate ban, claiming "the causal relationship is not clear."
Responsibility of experts: Some government-aligned scholars stated that "unheated products are safe," dulling the judgment of those in the field.
Just as with thalidomide and SMON, the 'myth of safety' and 'prioritizing interests' delayed the response.
5. Lawsuits and Accountability
Victims filed lawsuits across the country to hold the state and pharmaceutical companies accountable.
1996 (Osaka District Court) Former Ministry of Health and Welfare division director Takeshi Abe was found guilty of professional negligence resulting in death. The first and only case in history where an administrative official was held criminally liable for drug-induced suffering.
However, many senior officials at the Ministry of Health and Welfare and executives of pharmaceutical companies escaped punishment, and accountability remained limited.
The Ministry of Health, Labour and Welfare states the following: 'With the HIV-tainted blood products incident as a turning point, improvements in the transparency of pharmaceutical administration and the strengthening of safety measures were promoted.' (Ministry of Health, Labour and Welfare, 'History of Drug-Induced Suffering')
Victims' voices: 'Can it really be ended with just an apology and compensation, without anyone taking responsibility? Are our lives that cheap?' (From the statement by the HIV-tainted blood products plaintiffs' group)
6. Delayed Response and the Structure of Absent Accountability
Delayed response: Ignored warnings from overseas and continued to use non-heat-treated products.
Absent accountability: Although some individuals in charge were held criminally liable, the responsibility of the organization as a whole remained ambiguous.
Closing the curtain with compensation: There were apologies and settlements, but the structural problems were not resolved.
A structure where 'no one takes responsibility in any real sense' became the soil that reproduces drug-induced suffering.
7. Common Root Causes - A Question for the Present Day
The HIV-tainted blood products incident showed the same structure as thalidomide and SMON.
Prioritizing interests over safety
Delayed response that ignored warnings from overseas
A system where the individuals in charge are not punished
The HIV-tainted blood products incident is not a 'past event,' but a lesson that conveys the flaws of the system to the present. Furthermore, this structure is being repeated in the special approvals and side effect issues surrounding modern COVID-19 vaccines.
'Speed over safety,' 'causal relationship unknown,' 'no one is punished'—. Drug-induced suffering has changed its form and still exists before our eyes today.